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Background: Low dose reactive cow's milk (CM) allergic children are at high risk of persistent CM allergy
and a positive oral food challenge (OFC). The present study aimed to evaluate if the results of a very low
dose (VL) OFC with these children contributes to better management of CM allergy.
Methods: We retrospectively reviewed subjects with CM allergy who underwent a VL OFC with 3 mL
heated CM and had a previous allergic reaction to <25 mL heated CM in the 2 years before the OFC.
Subjects who passed the OFC were deﬁned as VL tolerant, and subjects who failed were deﬁned as VL
reactive. VL tolerant subjects increased the dose to 25 mL heated CM either during an OFC in our hospital
or gradually at home.
Results: Of the 83 subjects (median age, 4.3 years; range, 1.0e12.9 years) who were included, 41 (49.4%)
were VL tolerant, and 42 (51.6%) were VL reactive. Thirty-nine VL reactive subjects had skin and/or
respiratory symptoms during the OFC. Most reactions could be treated with an antihistamine and/or a
nebulized b2 agonist. The VL tolerant subjects consumed 3 mL heated CM or 10 g butter. Within the year
following the OFC, 18 VL tolerant subjects (45.0%), but none of the VL reactive subjects, were able to
consume 25 mL heated CM (p < 0.001).
Conclusions: A VL OFC allows the management of some low dose reactive CM allergic children to change
from complete avoidance to partial intake of CM.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
IgE-mediated cow's milk (CM) allergy is a common food allergy
in infancy.1e3 Many children tend to outgrow a CM allergy in early
childhood4,5: 50% by age 5 and 75% by the early teenage years based
on a review of natural history.4 However, some children continue to
suffer from CM allergy, and an oral food challenge (OFC) is needed
to assess the achievement of tolerance.6 Low dose reactive CM
allergic children are at a high risk of persistent CM allergy5 and a
positive OFC.7 Because high dose intakes for these children cause
severe reactions,8 the OFC must be conducted carefully.
Baked milk9,10 and milk oral immunotherapy (OIT)11e13 are
possible approaches for CM allergy. Because many CM allergic chil-
dren tolerate baked milk,9e11 it can improve the dietary variety inClinical Research Center for
al Hospital, 18-1, Sakuradai,
(M. Ebisawa).
ety of Allergology.
rgology. Production and hosting by Elsethese children, who then generally have a good prognosis with their
unheated CM allergy.12 However, the challenge food for baked milk
contains 0.5e1.3 g CMprotein (equivalent to 15e40mL CM),9e11 and
children who react to baked milk avoid CM completely.12
Milk OIT for CM allergic children reportedly contributes to
desensitization or threshold elevation,13e15 but it might be imprac-
tical or inconvenient in real life because of the need for daily inges-
tion and risk of possible adverse reactions.13 In addition, it is difﬁcult
to achieve desensitization with milk OIT for low dose reactive CM
allergic children, and there is a high rate of adverse reactions.14,15
Therefore, to identify strategies for better management of CM
allergy,weperformed avery lowdose (VL)OFC (3mLheatedCM) and
CM dose progression in CM allergic childrenwho had experienced a
previous reaction to <25 mL heated CM, based on our daily practice.
Methods
Study design
We retrospectively reviewed subjects with low dose CM re-
actions who underwent a VL OFC, which involves 3 mL heated CMvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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were deﬁned as VL tolerant, and subjects who failed the VL OFC
were deﬁned as VL reactive.
The results of the VL OFC are presented as the OFC positive rate
and symptoms and treatments administered during the OFC. The
results of CM dose progression based on our daily practice during
the year after the OFC are compared using the time to reach 25 mL
heated CM between the VL tolerant and VL reactive subjects.
Informed consent for the OFC and publication of the data was
obtained from the children's guardians. This studywas approved by
the Sagamihara National Hospital Ethics Committee and was con-
ducted in accordance with the Declaration of Helsinki. The research
plan was posted at Sagamihara National Hospital. However,
because this study was retrospective, registration in an interna-
tionally certiﬁed registry was not required.
Subject selection
Eligible subjects were childrenwho underwent VL OFC between
July 2012 and December 2013, had a previous allergic reaction to
<25 mL of heated CM (equivalent to 850mg CM protein) within the
2 years before the VL OFC (median, 12.2 months; range, 0.6e23.9
months) and had a positive CM-speciﬁc IgE. Previous allergic re-
actions were deﬁned as immediate reactions if they occurred
within 2 h after ingesting CM.Worsening of eczema or asthma after
ingesting CM was not included in the immediate reactions. If pre-
vious allergic reactions occurred because of accidental ingestion,
CM doses were calculated based on a conversion table constructed
by the research dieticians.
Assessment of baseline characteristics
The attending physician was responsible for diagnoses of other
food allergies, eczema, asthma, and allergic rhino-conjunctivitis.
Anaphylaxis was deﬁned as fulﬁlling the criteria proposed by Si-
mons et al.16
Laboratory test
CM-speciﬁc IgE was assessed using the ImmunoCAP assay sys-
tem (Thermo Fisher Scientiﬁc, Uppsala, Sweden) for all subjects,
and >0.35 kUA/L was considered positive. The median time be-
tween the laboratory test and VL OFC was 4.0 months (range,
0.0e22.5 months).
Oral food challenge protocol
The challenge food used in the VL OFC was pumpkin cake con-
taining CM, which was prepared by mixing 3 mL CM, 3 g pumpkin,
2 g sorghum bicolor, 1 g sugar, 0.02 g baking soda, and 1 mL water.
The mixture was heated to 90 C for 1.5 min in a 1000-W micro-
wave. For the OFC with 25 mL heated CM, we increased the in-
gredients by approximately 8 times the amount for the VL OFC
challenge food.
OFCs were performed openly under physician observation at
Sagamihara National Hospital. One-fourth of the VL OFC challenge
food was administered initially, and the remaining three-fourths
was administered 60 min later. The OFC was concluded when a
quantity of CM sufﬁcient to cause moderate or severe symptoms
(generalized urticaria, continuous coughing, moderate or severe
abdominal pain, vomiting, or diarrhoea) had been consumed. If
mild objective symptoms (localized urticaria or intermittent
coughing) appeared during the OFC, the subject was carefully
monitored to detect any worsening of symptoms. If the mild
objective symptoms disappeared within 30 min, the OFC wascontinued. When an adverse reaction occurred, treatment (anti-
histamine, nebulized b2 agonist, steroids, or adrenaline) was
administered based on the European Academy of Food Allergy and
Clinical Immunology (EAACI) food allergy and anaphylaxis
guidelines.17
Cow's milk dose progression and follow-up
Subjects who passed the VL OFCwere advised to consume a food
containing 3 mL heated CM or 10 g butter (equivalent to 2.9 mL
CM18) at home at least once a week. One to three months after the
OFC was passed, the CM dose was increased to 25 mL heated CM
either during an OFC in our hospital or gradually at home. With the
latter method, the heated CM dosewas increased by 1mL every few
consumptions. If adverse reactions appeared, the previous dose
was repeated. When the previous dose was passed, the scheduled
increase was attempted. Subjects who failed the VL OFC underwent
a second OFC at least 6 months from the ﬁrst OFC.
We prescribed antihistamines for all subjects, adrenaline auto-
injectors for the subjects with a history of anaphylaxis, and other
medications depending on complications. All subjects received
instructions on when and how to administer emergency medica-
tions and visit the emergency department.
Statistical analysis
Differences in characteristics at the time of the VL OFC were
compared between the VL tolerant and VL reactive subjects using
ManneWhitney tests for continuous variables (expressed as me-
dian and range) and chi-square or Fischer's exact tests for cate-
gorical variables (expressed as number and percentage).
CM dose progression was measured as the time to reach con-
sumption of 25 mL heated CM. KaplaneMeier curves were gener-
ated to depict the changes for the VL tolerant and VL reactive
subjects. The differences were estimated using the log-rank test.
SPSS version 20 (IBM Corp., Armonk, NY, USA) was used for all
analyses.
Results
Baseline subject characteristics
Of the 131 subjects who underwent the VL OFC between July
2012 and December 2013, 48 subjects were excluded for a previous
allergic reaction to CM more than 2 years prior, resulting in 83
subjects (median age, 4.3 years; range, 1.0e12.9 years) in the ana-
lyses (Fig. 1). The median CM-speciﬁc IgE level was 19.5 kUA/L
(range, 0.66e284 kUA/L) (Table 1). Baseline subject characteristics
were not signiﬁcantly different between the VL tolerant (n ¼ 41,
49.4%) and VL reactive (n ¼ 42, 51.6%) subjects (Table 1).
The subjects' previous allergic reactions were caused by acci-
dental ingestion (61.4%) or an OFC with CM (38.6%). The median
threshold dose at the previous OFC with CM was 12.5 mL (range,
3.0e25.0 mL) (Table 2). The threshold dose in the previous OFC
with CM was higher in the VL tolerant subjects than in the VL
reactive subjects, and rate of skin symptoms was lower in the VL
tolerant subjects than in the VL reactive subjects (Table 2).
Results of the very low dose oral food challenge
Respiratory symptoms were the most common symptom,
occurring in 83.3% (n ¼ 35) of the VL reactive subjects, followed by
skin symptoms, occurring in 81.0% (n ¼ 34) of the VL reactive
subjects. The majority of reactions were treated with antihista-
mines and/or nebulized b2 agonists. Among the 35 subjects with
Fig. 1. Flowchart of enrolled subjects to assess the use of an oral food challenge (OFC) for cow's milk allergies. The VL OFC was conducted with 3 mL heated cow's milk. VL, very low
dose; OFC, oral food challenge.
Y. Okada et al. / Allergology International 64 (2015) 272e276274respiratory symptoms, 4 (11.4%) received only antihistamines, 27
(77.2%) received 1 dose of a nebulized b2 agonist, 2 (5.7%) received
2 doses of nebulized b2 agonist, and 2 (5.7%) received 1 dose of
adrenaline. One subject received 1 dose of adrenaline for general-
ized urticaria with agitation (Table 3).Cow's milk dose progression based on our daily practice within the
year after the very low dose oral food challenge
Of the VL tolerant subjects, 14 underwent an OFC with 25 mL
heated CM, and 9 of these subjects passed the OFC. The remaining
27 VL tolerant subjects gradually increased the CM dose at home,
and 9 of these subjects reached 25 mL heated CM. Therefore, a total
of 18 (45.0%) VL tolerant subjects reached 25 mL heated CM.
Of the VL reactive subjects, 24 underwent a second VL OFC, and
only 3 subjects passed the second OFC. None (0.0%) of the VL
reactive subjects reached 25 mL heated CM (p < 0.001) (Fig. 2).Adverse reaction to cow's milk consumed at home
A 7-year-old boy had 2 reactionary episodes to 3 mL heated CM.
In the ﬁrst episode, moderate abdominal pain and persistent cough
occurred after CM intake that was followed by walking. The reac-
tion was treated with oral steroids and 1 dose of a nebulized b2
agonist. In the second episode, mild abdominal pain occurred after
CM intake. The subject did not consumemore than 4mL heated CM
during the year after the VL OFC.Table 1
Baseline characteristics of subjects with cow's milk allergy who underwent a very low d
Characteristic All subjects
(n ¼ 83)
Age (years) 4.3 (1.0e12.9)
Male sex 52 (62.7)
History of anaphylaxis to CM 49 (59.0)
Other food allergy, current 58 (69.9)
Eczema, current 59 (71.1)
Asthma, current 24 (28.9)
Allergic rhino-conjunctivitis, current 20 (24.1)
Total IgE (kUA/L) 429 (28.5e7290)
CM-speciﬁc IgE (kUA/L) 19.5 (0.66e284)
*Comparisons between the VL tolerant and VL reactive subjects were conducted using M
categorical variables.
Values are reported as median (range) or n (%).
VL, very low dose; CM, cow's milk.The heated CM dose could be increased in 40 subjects. Three
subjects (7.5%) each had 1 reactionary episode to 4e25 mL heated
CM. One subject had generalized urticaria, one subject had mild
abdominal pain, and the remaining subject had an intermittent
cough (Table 4). None of the adverse reactions required adrenaline
or a visit to the emergency department. There was no worsening of
eczema or asthma.Discussion
To the best of our knowledge, this is the ﬁrst study to indicate
that VL OFC could be used to help manage food allergies in children
with a low dose reactive CM allergy. Based on the OFC results, half
of the children in the present study could begin consuming very
low doses of CM products on a daily basis. Furthermore, approxi-
mately half of these VL-tolerant children could consume 25 mL
heated CM within the year following the VL OFC.
Regarding the deﬁnition of low dose reactive CM used in the
present study, we believe that it is appropriate because previous
studies have used 25e30 mL CM for low dose OFCs19,20; we deﬁned
low dose reactive CM allergy based on previous allergic reactions to
<25 mL heated CM.
Cianferoni et al. reported that non-skin symptoms at the pre-
vious reaction are predictors of OFC.21 However, the frequency of
skin symptoms at the previous reaction in the present study was
lower in the VL tolerant subjects than in the VL reactive subjects. In
the VL reactive subjects, 29 (72.5%) with skin symptom at theose oral food challenge.
VL tolerant VL reactive p value*
(n ¼ 41) (n ¼ 42)
4.3 (1.0e12.9) 4.0 (1.2e8.2) 0.774
24 (58.5) 28 (66.7) 0.444
21 (51.2) 28 (66.7) 0.152
27 (65.9) 31 (73.8) 0.430
28 (68.3) 31 (73.8) 0.579
11 (26.8) 13 (31.0) 0.679
8 (19.5) 12 (28.6) 0.335
521 (35.8e6090) 380 (28.5e7290) 0.906
19.7 (0.66e228) 19.2 (4.6e284) 0.112
anneWhitney tests for continuous variables or chi-square or Fischer's exact tests for
Table 3
Symptoms and administered treatments during the very low dose oral food
challenge with cow's milk.
VL reactive (n ¼ 42)
Symptoms
Skin (%) 34 (81.0)
Gastrointestinal (%) 13 (31.0)
Respiratory (%) 35 (83.3)
Cardiovascular (%) 0 (0.0)
Anaphylaxis (%) 30 (71.4)
Treatments
Antihistamine (%) 41 (97.6)
b2 agonist, nebulized (%) 31 (73.8)
Steroids (%) 5 (11.9)
Adrenaline (%) 3 (7.1)
The very low dose (VL) reactive subjects failed the VL oral food challenge,
which was conducted with 3 mL heated cow's milk.
Table 4
Adverse reaction to heated cow's milk at home after passing the very low dose oral
food challenge.
VL tolerant
Very low dose
(3 mL) (n ¼ 41)
Dose escalation
(4e25 mL) (n ¼ 40y)
No. (%) of subjects 1 (2.4) 3 (7.5)
No. of adverse reactions 2 3
Skin 0 1
Gastrointestinal 2 1
Respiratory 1 1
Cardiovascular 0 0
Anaphylaxis 1 0
The very low dose (VL) tolerant subjects passed the VL oral food challenge, which
was conducted with 3 mL heated cow's milk.
y One subject who had a reaction to 3 mL heated cow's milk at home did not
consume >4 mL heated cow's milk within the year following the very low dose oral
food challenge.
Table 2
Characteristics of previous allergic reaction to cow's milk.
Characteristic All subjects VL tolerant VL reactive p value*
(n ¼ 83) (n ¼ 41) (n ¼ 42)
Reason for previous allergic reaction to CM
Accidental
ingestion
51 (61.4) 25 (61.0) 26 (61.9) 0.931
OFC to CM 32 (38.6) 16 (39.0) 16 (38.1)
Threshold dose at
previous OFC
to CM (mL)
12.5 (3.0e25.0)
(n ¼ 32)
22.5 (9.4e25.0)
(n ¼ 16)
9.7 (3.0e25.0)
(n ¼ 16)
0.002
Symptom at previous allergic reaction to CM
Skin 73 (88.0) 33 (80.5) 40 (95.2) 0.040
Gastrointestinal 29 (34.9) 15 (36.6) 14 (33.3) 0.871
Respiratory 41 (49.4) 17 (41.5) 24 (57.1) 0.153
Cardiovascular 5 (6.0) 3 (7.3) 2 (4.8) 0.488
Anaphylaxis 49 (59.0) 21 (51.2) 28 (66.7) 0.152
*Comparisons between the VL tolerant and VL reactive subjects were conducted
using ManneWhitney tests for continuous variables or chi-square or Fischer's exact
tests for categorical variables. Statistically signiﬁcant p values (<0.05) are in bold.
Values are reported as median (range) or n (%).
VL, very low dose; CM, cow's milk; OFC, oral food challenge.
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tolerant subjects (60.6%) with skin symptoms. Hence, it is possible
that the severity of previous reactions and the threshold dose of a
previous OFC with CM are predictors of VL OFC results.
Although many of the VL reactive subjects had skin and respi-
ratory symptoms during the VL OFC, these reactions were treatable
with antihistamines and/or nebulized b2 agonists. Compared with
subjects who underwent an OFC with baked milk in previousFig. 2. KaplaneMeier curves showing the time to achieve consumption of 25 mL
heated cow's milk during the year after very low dose oral food challenge for cow's
milk allergy. VL, very low dose; CM, cow's milk.studies, the CM-speciﬁc IgE of our subjects was higher (median of
subjects who failed the OFC in the present study, 19.2 kUA/L vs.
2.39e11.6 kUA/L), whereas the rate of adrenaline treatment in our
subjects was lower (7% vs. 16e35%).9,10 Because of the high
anaphylaxis rate, our adrenaline use may appear inappropriate.
However, many respiratory symptoms were equivalent to mild
wheezing as deﬁned in the EAACI taskforce position paper,22 and
most of the reactions were mild to moderate, even in those low
dose reactive CM allergic children who failed the VL OFC.
Almost all of the VL tolerant subjects were able to safely
consume 3mL heated CM at home. One 7-year-old boy experienced
moderate symptoms because of exercise, which is a known
cofactor, in addition to infections and use of non-steroidal anti-
inﬂammatory drugs.6 Although the children's guardians may need
to aware of these cofactors, VL tolerant children can start to
consume very low doses of CM and butter.
Previous studies suggest that VL intake several times per week
improves food allergy. For example, Peters et al. reported that
baked egg ingestion 1e4 times per month resulted in a higher
resolution of raw egg allergy compared with no consumption.23
Regarding VL intake, CM sublingual immunotherapy (0.1 mL of
initial dose24 and 3.7 mg of maintenance dose25) increased the food
challenge threshold approximately three-to sevenfold.24,25
The limitations of our retrospective study include the lack of
measurement of an accurate threshold using an OFC with a regular
dose just before the VL OFC and the lack of a control group that did
not undergo the VL OFC. An OFC with a regular dose in the control
group would have provided information about the normal change in
the food challenge threshold. We did not perform regular dose OFCs
in the low dose reactive CM allergic children to avoid severe re-
actions. Based on the ﬁndings of the present study, we plan to
conduct a prospective study of VL OFCs for these children. The
heatingmethod is another limitation. Our challenge foodwas heated
to 90 C for 1.5 min in a 1000-W microwave, while baked milk as a
challenge food is baked at 180 C for 20e30 min in an oven,9e11
which makes comparisons with baked milk studies difﬁcult.
In conclusion, VL OFC helps to identify those low dose reactive
CM allergic children who can shift from complete avoidance to
partial intake of CM, providing better management of these chil-
dren. Future randomized controlled trials are needed to determine
if partial intake of CM improves CM allergy.Acknowledgements
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